Trial Profile
Iron Deficiency and Fibroblast Growth Factor 23 Regulation in Chronic Kidney Disease and Heart Failure
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Iron sucrose (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Acronyms INDIGO
- 18 Mar 2019 Status changed from recruiting to completed.
- 12 Apr 2017 New trial record